{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:42:04Z","timestamp":1783464124265,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"DOI":"10.7759\/cureus.97915","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:13:42Z","timestamp":1764238422000},"source":"Crossref","is-referenced-by-count":1,"title":["Role of FXR Agonist in Cholestasis Following Live Donor Liver Transplantation: A Randomized Open-Label Trial"],"prefix":"10.7759","author":[{"given":"Anila","family":"KN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswathy","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnikrishnan","family":"G","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiya Muhammed","family":"Zackariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haritha","family":"Rajakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajana","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhindran","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi H","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023, 79:516-37. 10.1016\/j.jhep.2023.03.017","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000456580","article-title":"Lessons from epidemiology: the burden of liver disease","volume":"35","author":"Rowe IA","year":"2017","unstructured":"Rowe IA. Lessons from epidemiology: the burden of liver disease. Dig Dis. 2017, 35:304-9. 10.1159\/000456580","journal-title":"Dig Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016, 64:433-85. 10.1016\/j.jhep.2015.10.006","journal-title":"J Hepatol"},{"key":"ref4","unstructured":"Global health estimates. Leading causes of death. (2020). Accessed:  August 11, 2025: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15276","article-title":"OPTN\/SRTR 2017 annual data report: liver","volume":"19 Suppl 2","author":"Kim WR","year":"2019","unstructured":"Kim WR, Lake JR, Smith JM, et al.. OPTN\/SRTR 2017 annual data report: liver. Am J Transplant. 2019, 19 Suppl 2:184-283. 10.1111\/ajt.15276","journal-title":"Am J Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.11-5-506","article-title":"Sherlock's disease of the liver and biliary systems","volume":"11","author":"Williams R","year":"2011","unstructured":"Williams R. Sherlock's disease of the liver and biliary systems. Clin Med (Lond). 2011, 11:506. 10.7861\/clinmedicine.11-5-506","journal-title":"Clin Med (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50212","article-title":"Intrahepatic cholestasis after liver transplantation","volume":"9","author":"Ben-Ari Z","year":"2003","unstructured":"Ben-Ari Z, Pappo O, Mor E. Intrahepatic cholestasis after liver transplantation. Liver Transpl. 2003, 9:1005-18. 10.1053\/jlts.2003.50212","journal-title":"Liver Transpl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S91709","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection","volume":"8","author":"Bowlus CL","year":"2016","unstructured":"Bowlus CL. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepat Med. 2016, 8:89-95. 10.2147\/HMER.S91709","journal-title":"Hepat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0264-1","article-title":"Obeticholic acid for the treatment of NASH","volume":"17","author":"Hindson J","year":"2020","unstructured":"Hindson J. Obeticholic acid for the treatment of NASH. Nat Rev Gastroenterol Hepatol. 2020, 17:66. 10.1038\/s41575-020-0264-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/00365529409103627","article-title":"A possible role of ursodeoxycholic acid in liver transplantation","volume":"204","author":"Friman S","year":"1994","unstructured":"Friman S, Svanvik J. A possible role of ursodeoxycholic acid in liver transplantation. Scand J Gastroenterol Suppl. 1994, 204:62-4. 10.3109\/00365529409103627","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2014.12.06","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali AH","year":"2015","unstructured":"Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015, 3:5. 10.3978\/j.issn.2305-5839.2014.12.06","journal-title":"Ann Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_231","article-title":"Targeting FXR in cholestasis","volume":"256","author":"Keitel V","year":"2019","unstructured":"Keitel V, Dr\u00f6ge C, H\u00e4ussinger D. Targeting FXR in cholestasis. Handb Exp Pharmacol. 2019, 256:299-324. 10.1007\/164_2019_231","journal-title":"Handb Exp Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/0127724328239536230919070001","article-title":"A short review on obeticholic acid: an effective modulator of farnesoid X receptor","volume":"19","author":"Narayanan AK","year":"2024","unstructured":"Narayanan AK, Surendran S, Balakrishnan D, et al.. A short review on obeticholic acid: an effective modulator of farnesoid X receptor. Curr Rev Clin Exp Pharmacol. 2024, 19:225-33. 10.2174\/0127724328239536230919070001","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki T","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, et al.. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-25. 10.1016\/j.cmet.2005.09.001","journal-title":"Cell Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2021.02.002","article-title":"Farnesoid X receptor and fibroblast growth factor 15\/19 as pharmacological targets","volume":"5","author":"Maliha S","year":"2021","unstructured":"Maliha S, Guo GL. Farnesoid X receptor and fibroblast growth factor 15\/19 as pharmacological targets. Liver Res. 2021, 5:142-50. 10.1016\/j.livres.2021.02.002","journal-title":"Liver Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-006-0062-9","article-title":"Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)","volume":"453","author":"Oude Elferink RP","year":"2007","unstructured":"Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007, 453:601-10. 10.1007\/s00424-006-0062-9","journal-title":"Pflugers Arch"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/srep30847","article-title":"Serum Autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases","volume":"6","author":"Wunsch E","year":"2016","unstructured":"Wunsch E, Krawczyk M, Milkiewicz M, et al.. Serum Autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases. Sci Rep. 2016, 6:30847. 10.1038\/srep30847","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein AE","year":"2009","unstructured":"Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009, 50:1072-8. 10.1002\/hep.23050","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley S","year":"2012","unstructured":"Dooley S, ten Dijke P. TGF-\u03b2 in progression of liver disease. Cell Tissue Res. 2012, 347:245-56. 10.1007\/s00441-011-1246-y","journal-title":"Cell Tissue Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000226385.71859.5f","article-title":"Bile salt excretory pump: biology and pathobiology","volume":"43 Suppl 1","author":"Suchy FJ","year":"2006","unstructured":"Suchy FJ, Ananthanarayanan M. Bile salt excretory pump: biology and pathobiology. J Pediatr Gastroenterol Nutr. 2006, 43 Suppl 1:S10-6. 10.1097\/01.mpg.0000226385.71859.5f","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile acids and FXR: novel targets for liver diseases","volume":"7","author":"Stofan M","year":"2020","unstructured":"Stofan M, Guo GL. Bile acids and FXR: novel targets for liver diseases. Front Med (Lausanne). 2020, 7:544. 10.3389\/fmed.2020.00544","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250328","article-title":"Banff schema for grading liver allograft rejection: an international consensus document","volume":"25","year":"1997","unstructured":"Banff schema for grading liver allograft rejection. an international consensus document. Hepatology. 1997, 25:658-63. 10.1002\/hep.510250328","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2022.02.019","article-title":"The utility of early allograft dysfunction components in determining 90-day liver graft survival","volume":"54","author":"Figiel W","year":"2022","unstructured":"Figiel W, Smoter P, Krasnod\u0119bski M, et al.. The utility of early allograft dysfunction components in determining 90-day liver graft survival. Transplant Proc. 2022, 54:1017-20. 10.1016\/j.transproceed.2022.02.019","journal-title":"Transplant Proc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi ZM","year":"1999","unstructured":"Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999, 45:295-300. 10.1136\/gut.45.2.295","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann AF","year":"1999","unstructured":"Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999, 159:2647-58. 10.1001\/archinte.159.22.2647","journal-title":"Arch Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard K","year":"2021","unstructured":"Kj\u00e6rgaard K, Frisch K, S\u00f8rensen M, et al.. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. J Hepatol. 2021, 74:58-65. 10.1016\/j.jhep.2020.07.028","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016, 375:631-43. 10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield GM","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, et al.. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015, 148:751-61.e8. 10.1053\/j.gastro.2014.12.005","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260408","article-title":"A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection","volume":"26","author":"Barnes D","year":"1997","unstructured":"Barnes D, Talenti D, Cammell G, et al.. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology. 1997, 26:853-7. 10.1002\/hep.510260408","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1159\/000339711","article-title":"Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial","volume":"86","author":"Wang SY","year":"2012","unstructured":"Wang SY, Tang HM, Chen GQ, et al.. Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial. Digestion. 2012, 86:208-17. 10.1159\/000339711","journal-title":"Digestion"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley KV","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, et al.. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018, 67:1890-902. 10.1002\/hep.29569","journal-title":"Hepatology"},{"key":"ref33","unstructured":"Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis. (2024). Accessed.  August 02, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/serious-liver-injury-being-observed-patients-without-cirrhosis...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409898-role-of-fxr-agonist-in-cholestasis-following-live-donor-liver-transplantation-a-randomized-open-label-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:13:47Z","timestamp":1764238427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409898-role-of-fxr-agonist-in-cholestasis-following-live-donor-liver-transplantation-a-randomized-open-label-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.97915","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}